Main menu

Post navigation

BMS-354825 Dasatinib was approved for marketing in Israel L ao

Mitoxantrone was selected BMS-354825 Dasatinib as a control group in this study because of its h Ufigen use in the practice of the weight. Recently, after the Food and Drug Administration has approved cabazitaxel in June 2010, was the drug of the Brazilian National Health Surveillance Agency approved will be administered in combination with prednisone or prednisolone for the treatment of metastatic docetaxel CPRC. Zus Tzlich to the United States, cabazitaxel , Curac ? and the Europ European Union plus Iceland, Liechtenstein and Norway. Abiraterone Abiraterone is a selective inhibitor of androgen biosynthesis by its action on 17 cytochrome P450, the key enzyme in the biosynthesis of androgens and Estrogens.
On the basis of evidence that CRPC remains sensitive to androgens from the adrenal gland or endocrine synthesis, have pr Clinical studies suggested that abiraterone is effective CRPC. There were also a phase I / II study of a PSA response for almost two thirds of 42 patients with chemotherapy had ? ? CRPC. Compared in a phase III trial, abiraterone with placebo, each in combination with prednisone was, in 1196, in patients with metastatic docetaxel CRPP. The prime Re endpoint of OS was significantly different between the two groups, there was a 35% reduction in the risk of death and a median survival time of 14.8 months versus 10.9 months with abiraterone in the placebo group. The secondary Ren endpoints such as PFS, TTP, and PSA response, always in favor of abiraterone group and the toxicity of t this substance were mainly Hypokali Chemistry and fluid retention.
Based on the results of this study, the FDA approved abiraterone in combination with prednisone for the treatment of docetaxel in metastatic patients CRAC in April 2011. Sipuleucel T immunological mechanisms influence the behavior of prostate cancer and other cancers. Sipuleucel T, one type of therapeutic cancer vaccine may cellular Ren immune responses by active peripheralblood autologous mononuclear Re cells ex vivo stimulated with a recombinant fusion protein comprising the prostatic acid phosphatase, and the activator, the activated immune cells inducing factor, granulocyte-macrophage colony . The use of T Sipuleucel includes harvesting mononuclear Ren cells from the peripheral blood of the patient cultured with the fusion protein and antigen pr Presenting cells are infused into the patient.
The combined analysis of two relatively small randomized trials showed that Sipuleucel T produces a survival advantage in 225 patients with CRPC compared to those treated with placebo, there was an acceptable side-effect profile, the Haupt. Chlich from chills, fever and headache A third of placebo embroidered stripes in phase III clinical trials have been started, and 512 patients were in the ratio Randomized 2:1 ratio to receive either intravenous placebo Sipuleucel T S. Every 2 weeks for a total of three injections The study showed a 22% reduction in relative risk of death with the use of Sipuleucel T, which is an improvement of 4.1 months median. However, the TTP was similar in both study groups, has found this to be relatively rare in medical oncology has been identified as a surprising and deserves to be investigated further, probably to the mechanism in the context